Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,734 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,061 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06856187 | Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer(TASBEL) | recruiting | Phase 2 | 119 | Fudan UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07105852 | Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma | recruiting | Phase 2 | 59 | Sir Run Run Shaw HospitalOTHER | 1 | Aug 6, 2025 |
| clinicaltrials |
| NCT07108127 | Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer(NePHera) | recruiting | Phase 2 | 24 | Peking Union Medical College HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06551272 | Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma(MOTHER) | recruiting | Phase 2 | 34 | Center Eugene MarquisOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT03493048 | Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM | active not recruiting | Phase 2 | 146 | Sun Yat-sen UniversityOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07025850 | Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 20 | Fudan UniversityOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07098598 | Pancreatic Cancer Diagnosis With FAPI-PET Imaging | recruiting | Phase 2 / Phase 3 | 100 | Turku University HospitalOTHER_GOV | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07099794 | A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen | not yet recruiting | Phase 2 | 90 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases(ASAC) | active not recruiting | Phase 2 / Phase 3 | 466 | Oslo University HospitalOTHER | 3 | Jul 31, 2025 | clinicaltrials |
| NCT07085273 | Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer | not yet recruiting | Phase 2 | 33 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jul 31, 2025 | clinicaltrials |
| NCT07095309 | Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer(NeoART-M) | not yet recruiting | Phase 2 | 120 | Metanoic Health Ltd.INDUSTRY | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07095439 | Efficacy and Toxicity of Total Neoadjuvant Sandwich Treatment Via Short Course Radiotherapy in the Treatment of Stage II and III Rectal Cancer Patients | recruiting | Phase 2 | 38 | Ain Shams UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07097064 | Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers(RAIPANC) | not yet recruiting | Phase 2 | 160 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06441565 | Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06695026 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 45 | Rznomics, Inc.OTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06732856 | A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer(NEO-CLAUD) | recruiting | Phase 1 / Phase 2 | 57 | Asan Medical CenterOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT03421288 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness(DANTE) | active not recruiting | Phase 2 | 677 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Jul 25, 2025 | clinicaltrials |
| NCT03806309 | OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC(TEDOPAM) | active not recruiting | Phase 2 | 106 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06846268 | Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer | recruiting | Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085169 | Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC | recruiting | Phase 2 | 50 | Ruijin HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06819566 | Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC(ESCOAT) | recruiting | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06940388 | Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.(TOTAL) | recruiting | Phase 2 | 134 | brenner baruchOTHER | 2 | Jul 24, 2025 | clinicaltrials |
| NCT03704480 | Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.(IMMUNO-BIL) | active not recruiting | Phase 2 | 106 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04268121 | Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas(NEONEC) | recruiting | Phase 2 | 78 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05571644 | Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer(OPTICAL-2) | recruiting | Phase 2 | 143 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05604560 | A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer | active not recruiting | Phase 2 | 25 | Lei ZhengOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06031285 | Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial | recruiting | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07078305 | Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment | not yet recruiting | Phase 2 | 134 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07046221 | Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery | not yet recruiting | Phase 2 | 60 | Fujian Cancer HospitalOTHER_GOV | 0 | Jul 20, 2025 | clinicaltrials |
| NCT07075419 | JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 0 | Jul 20, 2025 | clinicaltrials |
| NCT06329973 | Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer | recruiting | Phase 1 / Phase 2 | 70 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07071844 | BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients(BETWEEN) | not yet recruiting | Phase 2 | 162 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05173246 | JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma | recruiting | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06427252 | The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM | active not recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07064668 | Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study | not yet recruiting | Phase 2 | 300 | Tongji HospitalOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07066995 | Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer(BAH2573-102) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07062328 | A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC(HP-BTC-002) | not yet recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07063888 | A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 66 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04592211 | Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer | recruiting | Phase 1 / Phase 2 | 71 | Yonsei UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05894824 | T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 58 | Yonsei UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT06873763 | Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 52 | STCube, Inc.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT07059949 | Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer(Union-mRC) | not yet recruiting | Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jul 11, 2025 | clinicaltrials |
| NCT07059338 | Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer(HERBIC) | not yet recruiting | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07053150 | A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors(CCGLC-018) | not yet recruiting | Phase 2 | 80 | Tongji HospitalOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07053488 | CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection | recruiting | Phase 1 / Phase 2 | 90 | AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLCOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT05797805 | A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 178 | Iterion TherapeuticsINDUSTRY | 2 | Jul 4, 2025 | clinicaltrials |
| NCT07051785 | Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer(ARK) | not yet recruiting | Phase 2 | 68 | Liu HuangOTHER | 0 | Jul 4, 2025 | clinicaltrials |
| NCT06630624 | Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM(INJECTABL-II) | recruiting | Phase 1 / Phase 2 | 120 | M.R. MeijerinkOTHER | 1 | Jul 3, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Aug 6, 2025source: clinicaltrials